How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

Company Overview - Kenvue Inc. is a global consumer health company headquartered in Summit, New Jersey, with a market cap of approximately $34.8 billion, categorizing it as a large-cap company [1] - The company focuses on everyday health and personal care products, maintaining a diverse portfolio that addresses a wide range of daily health needs [1] Product Portfolio - Kenvue offers over-the-counter treatments for various health issues, including cough, cold, allergies, pain relief, and digestive health, alongside skincare, haircare, oral care, and baby care products [2] - The company features well-known brands such as Tylenol, Benadryl, Zyrtec, Neutrogena, Aveeno, Listerine, BAND-AID, and Johnson's, which have built consumer trust over decades [2] Stock Performance - Kenvue's stock is currently trading 28.7% below its 52-week high of $25.17 reached in May 2025, with a modest increase of 3.7% over the past three months [3] - Over the last 52 weeks, Kenvue's shares have declined by 24.9%, although there has been a 4.1% gain year-to-date (YTD) [6] - In comparison, the State Street Consumer Staples Select Sector SPDR ETF (XLP) has increased by 3.7% over the same 52-week period and surged by 10.4% in 2026 [6] Technical Indicators - Since mid-November 2025, Kenvue's shares have mostly traded above their 50-day moving average of $17.85, indicating short-term stability [7] - However, the stock has consistently remained below its 200-day moving average of $18.75 since August 2025, suggesting a lack of investor confidence in the stock's long-term trajectory [7] Financial Performance - In the latest earnings release on February 17, 2025, Kenvue reported Q4 revenue of $3.78 billion, reflecting a year-over-year increase of 3.2% and surpassing Street expectations of $3.71 billion [8]